Starpharma Holdings Debt 2024

Starpharma Holdings Aktienanalyse

What does Starpharma Holdings do?

Starpharma Holdings Ltd is an Australian company specializing in the development of innovative solutions in the fields of pharmacy and biotechnology. The company was founded in 1996 and has since written an impressive history full of successful developments and numerous partnerships. The main business of Starpharma focuses on the development and commercialization of drugs and other health products based on dendrimer technology. One of the most advanced applications of dendrimer technology is VivaGel, a topical gel for the prevention of sexually transmitted diseases, particularly HPV (Human Papillomavirus). VivaGel is based on a dendrimer that acts both as an antiviral agent and an antibiotic, capable of preventing infection by different types of HPV. The product has already undergone Phase III clinical trials and is currently being marketed worldwide. In addition to VivaGel, Starpharma also offers dendrimer-based technologies and services in the field of drug development. The company has formed numerous partnerships with major pharmaceutical companies such as AstraZeneca, GSK, and Merck, and is involved in the development of drugs for cancer, autoimmune diseases, and infectious diseases. Furthermore, Starpharma has expanded its dendrimer technology to other industries, such as agriculture, where dendrimers can contribute to improving soil quality and reducing pesticide use. In this sector, Starpharma has also formed partnerships with agricultural companies such as Adama and Nufarm. Overall, Starpharma is a company that has experienced significant growth in recent years and continues to focus on the development of new and innovative products and solutions. Its core competence in dendrimer technology has allowed it to establish itself as a key player in various industries and build numerous partnerships with global companies. With its diverse range of products and services and a strong focus on research and development, Starpharma can be considered an important player in the field of biotechnology and healthcare innovations. Indicate the sector in starpharma specialize in. Starpharma Holdings ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Debt Details

Understanding Starpharma Holdings's Debt Structure

Starpharma Holdings's total debt refers to the cumulative financial obligations the company owes to external parties. This can include short-term and long-term borrowings, bonds, loans, and other financial instruments. Assessing the company's debt levels is crucial for evaluating its financial health, risk profile, and ability to fund operations and expansions.

Year-to-Year Comparison

Analyzing Starpharma Holdings's debt structure over the years provides insights into the firm’s financial strategy and stability. A reduction in debt can indicate financial strength and operational efficiency, while an increase may signal growth investments or potential financial challenges ahead.

Impact on Investments

Investors pay close attention to Starpharma Holdings’s debt levels as they can influence the company’s risk and return profiles. Excessive debt can lead to financial strain, while moderate and well-managed debt can be a catalyst for growth and expansion, making it a critical aspect of investment evaluations.

Interpreting Debt Fluctuations

Shifts in Starpharma Holdings’s debt levels can be attributed to various operational and strategic factors. An increase in debt might be geared towards funding expansion projects or enhancing operational capacity, while a decrease may indicate profit realizations or an approach to minimize financial risk and leverage.

Frequently Asked Questions about Starpharma Holdings stock

What is the debt of Starpharma Holdings this year?

Starpharma Holdings has a debt level of -19.83 AUD this year.

What was the debt of Starpharma Holdings compared to the previous year?

The debt of Starpharma Holdings has increased by -52.47% compared to the previous year dropped.

What are the consequences of high debt for investors in Starpharma Holdings?

High debt can pose a risk for investors of Starpharma Holdings, as it can weaken the company's financial position and hinder its ability to fulfill its obligations.

What are the consequences of low debt for investors of Starpharma Holdings?

Low debt means that Starpharma Holdings has a strong financial position and is able to fulfill its obligations without overburdening its finances.

How does an increase in debt from Starpharma Holdings affect the company?

An increase in debt of Starpharma Holdings can adversely affect the financial condition of the company and result in a higher burden on its finances.

How does a reduction of debt of Starpharma Holdings affect the company?

A reduction in debt of Starpharma Holdings can strengthen the company's financial position and improve its ability to meet its financial obligations.

What are some factors that influence the debt of Starpharma Holdings?

Some factors that can influence the debt of Starpharma Holdings include investments, acquisitions, operating costs, and revenue development.

Why are the debts of Starpharma Holdings so important for investors?

The debts of Starpharma Holdings are important for investors as they serve as an indicator of the company's financial stability. It provides investors with information on how the company fulfills its financial obligations.

What strategic measures can Starpharma Holdings take to change the debt?

To change the debt, Starpharma Holdings can take measures such as cost savings, increasing revenue, selling assets, making investments, or forming partnerships. It is important for the company to conduct a thorough review of its financial situation to determine the best strategic actions to change its debt.

How much dividend does Starpharma Holdings pay?

Over the past 12 months, Starpharma Holdings paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Starpharma Holdings is expected to pay a dividend of 0 AUD.

What is the dividend yield of Starpharma Holdings?

The current dividend yield of Starpharma Holdings is .

When does Starpharma Holdings pay dividends?

Starpharma Holdings pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Starpharma Holdings?

Starpharma Holdings paid dividends every year for the past 0 years.

What is the dividend of Starpharma Holdings?

For the upcoming 12 months, dividends amounting to 0 AUD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Starpharma Holdings located?

Starpharma Holdings is assigned to the 'Health' sector.

Wann musste ich die Aktien von Starpharma Holdings kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Starpharma Holdings from 9/20/2024 amounting to 0 AUD, you needed to have the stock in your portfolio before the ex-date on 9/20/2024.

When did Starpharma Holdings pay the last dividend?

The last dividend was paid out on 9/20/2024.

What was the dividend of Starpharma Holdings in the year 2023?

In the year 2023, Starpharma Holdings distributed 0 AUD as dividends.

In which currency does Starpharma Holdings pay out the dividend?

The dividends of Starpharma Holdings are distributed in AUD.